About: Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.12 (-2.30%)
ALT NASDAQ Altimmune Inc
Altimmune Inc share price
Atividade de preço de ALT
Último preço
$ 2,120
Variação (24h)
-0,05 USD (2,30%)
Volume
2.59M
Volume (média 4 sem.)
-
Abertura
$ 2,16
Variação do dia
$ 2,06 - $ 2,20
Fechamento anterior
$ 2,17
Último negócio
23 Oct, 8:07 pm GMT+0
Atrasado
23 Oct, 8:07 pm GMT+0
ALT price performance
Atrasado
23 Oct, 8:07 pm GMT+0
quote.marketSignals